The FDA has given Amgen (AMGN) the green light to bring its breakthrough lung cancer drug Lumakras to the market. Amgen is a global biotechnology company that focuses on developing solutions to address unmet medical needs.
Lumakras won accelerated regulatory approval to treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults. The FDA approval was based on the outcome of the CodeBreak 100 clinical trial program.
Of the 2.2 million new lung cancer cases…

Click here to view the original article.